CA
KYMR icon

CoreCap Advisors’s Kymera Therapeutics KYMR Stock Holding History

CoreCap Advisors’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28
Closed -$766 – 3027
2025
Q1 		$766 Buy
28
+12
+75% +$437 ﹤0.01% 2585
2024
Q4 		$644 Buy
+16
New +$723 ﹤0.01% 2448

Other funds holding KYMR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

CoreCap Advisors's KYMR Position: Q2 2025 in Review

CoreCap Advisors sold out of Kymera Therapeutics (KYMR) in Q2 2025, closing a stake of 28 shares — an estimated $766 sold.

CoreCap Advisors first reported a position in KYMR in Q4 2024 and held it in 2 quarters. The position peaked at $766 in Q1 2025. 210 funds tracked by Wall St. Rank hold KYMR as of Q2 2025.

  • CoreCap Advisors reported no remaining Kymera Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 28 Kymera Therapeutics shares in Q2 2025, an estimated $766.
  • CoreCap Advisors first reported a position in Kymera Therapeutics in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Kymera Therapeutics position peaked at $766 in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.